Abstract

The invention relates to the field of cancer therapy, especially by inducing cell death of malignant B cells by activating RIPK3 signaling pathway in these cells. The invention thus involves activating RIPK3 signaling pathway in malignant B cells for treating a patient in need thereof. The activation of RIPK3 signaling pathway in malignant B cells has in particular been shown to be beneficial against tumor growth, in particular when combined with an agonist of MLKL (like type I IFN) and/or a caspase inhibitor that optimize direct tumor cell death and subsequent anti-tumor immune response.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 38/21 - Interferons
• A61K 38/45 - Transferases (2)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Plasmodium falciparum50Plasmodium falciparum50P. falciparum50P. falciparum5050 value= 0.99 µM. The present invention thus relates to the use of ravidasvir, velpatasvir, and elbasvir for blocking transmission of Plasmodium gametocytes.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/65 - Tetracyclines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 33/06 - Antimalarials

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome -related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention concerns a multivalent immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV), wherein each valence is constituted by a recombinant live attenuated Mopeia virus in which the MOPV nucleoprotein (NP) has attenuated exonuclease activity and the encoded glycoprotein precursor (GPC) is from a New World arenavirus selected from one of the following arenaviruses: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV). The invention also concerns a combination of active ingredients, a composition or vaccine, or a therapeutically effective composition, comprising such recombinant live attenuated Mopeia viruses (MOPV) for use in eliciting a protective immune response in a mammalian host against a New World arenavirus infection. The invention also concerns a method of preparing such recombinant live attenuated Mopeia viruses (MOPV) in a eukaryotic host cell and a method of preparing a multivalent, in particular a pentavalent, immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV) expressing a GPC protein of a New World arenavirus selected among: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV).

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. The composition can include one or more non-VOC bio-based solvents chosen from the group of esters of aliphatic monocarboxylic acids, two or more bio-based non-ionic surfactants, and an anti-foaming agent. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

IPC Classes  ?

• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01P 7/04 - Insecticides

Abstract

The invention relates to immunocytokines comprising an anti-CTLA-4 antibody fused to a Treg-specific IL-2 receptor antagonist and their use to selectively deplete tumor-associated Tregs, in particular for treating cancer.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C07K 14/55 - IL-2
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Clostridioides difficileClostridioides difficile.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a method for reprogramming CD8+ T cells to enhance their therapeutic potential and its applications, in particular in adoptive T cell therapy for the treatment of infectious diseases and cancer.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to anti-ACE2 peptidase domain single domain antibodies. Further, the present invention relates to anti-ACE2 single domain antibodies comprising the CDR regions of the present single domain antibodies, polypeptides comprising thereof such as multimers thereof, and fusion proteins comprising thereof, as well as pharmaceutical compositions comprising the single domain antibodies, the polypeptides comprising thereof such as the multimeric single domain antibodies thereof, or the fusion proteins comprising thereof, and their use for treating diseases caused by a virus having ACE2 as receptor.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention relates to the field of immunity against coronaviruses. In this respect, the invention provides a lentiviral-based immunogenic agent that is suitable for use in boost or target immunization treatment in a subject, in particular a human subject, who had previously developed an immunity against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) based on: (i) vaccination with the first generation of vaccines against SARS-CoV-2 infection or disease such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine composition against SARS-CoV-2 infection or disease, in particular a protein- or an mRNA-based vaccine, or (ii) SARS-CoV-2-induced or correlated disease. The invention accordingly concerns a lentiviral-based immunogenic agent that in particular may help overcome the deficiencies of available vaccines against SARS-CoV-2, especially may be efficient in overcoming the waning immune response or insufficient cellular memory response observed after immunization with available first generation of vaccines such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine, in particular protein or mRNA vaccine, by triggering a mucosal humoral and cellular immune response against coronaviruses, including a long-lasting immune response.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants

Abstract

A method for genotyping a plasmodium comprising: (a) providing a sample containing a Plasmodium; and (b) detecting the presence of an increased copy number of the genomic plasmepsin2-3 cluster. A method for the detection of a plasmodium infection in a patient comprising: (a) providing a blood sample from a patient and (b) detecting the presence or absence of an increased copy number of the genomic plasmepsin2-3 cluster in the blood sample. Kits for genotyping a plasmodium and/or detection of a plasmodium infection. Methods of treating a plasmodium infection.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to an in vitro method for analyzing DNA interactions and kits for implementing said method. The method of the invention is more particularly useful for analyzing interactions between i) single-strand DNA (ssDNA) and ii) double-strand or single- strand DNA (dsDNA or ssDNA).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The invention discloses a lentiviral vector and lentiviral vector particles for treating hepatitis B infection. The lentiviral vector and particles of the invention contain a nucleotide sequence coding an hepatitis B virus antigen. The large S antigen of hepatitis B virus was in particular selected as candidate and can be applied in pharmaceutical compositions or vaccines for treating and/or preventing hepatitis B virus infection or treating and/or preventing diseases caused by hepatitis B virus infection, which has excellent therapeutic and preventive effects in subjects in need thereof.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A medical device for the delivery of a therapeutic agent by bioprinting including a rod body including a bioprinting cartridge arranged near the distal end of the rod body including a top layer including a solution containing a therapeutic agent; and an absorbent compound capable of converting light energy from laser radiation into thermal energy and arranged to cause heating of the solution including a therapeutic agent to cause a jet of the solution; an optical fiber extending longitudinally within a lumen of the rod body to deliver laser flow onto the absorbing compound.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes

Abstract

A recombinant lentiviral vector comprising a coding sequence for an OR protein fused to a coding sequence for a fluorescent protein or a subunit of a fluorescent protein, and a promoter active in human cells operatively linked to the coding sequences. A recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription. A recombinant eukaryotic cell comprising a genomically integrated DNA copy of the recombinant lentiviral vector. A method of observing lentiviral DNA in a eukaryotic cell, comprising: providing a recombinant eukaryotic cell that produces a fusion protein comprising an OR protein, fused to a fluorescent protein or a subunit of a fluorescent protein: infecting the recombinant eukaryotic cell with a recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription, under conditions sufficient for reverse transcription of the recombinant lentiviral genome comprising an ANCH sequence: allowing the OR protein to bind to the ANCH sequence; and detecting the fluorescent protein or subunit of the fluorescent protein to thereby observe the lentiviral DNA in the eukaryotic cell. This tool can be suitable also for in vivo applications (e.g. humanized mice) as well as for screening of new antiretroviral compounds. The HIV-1 ANCHOR system can be extended to the study of other viruses or for the screening of antiviral compounds, e.g. against SARS-COV2.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 15/86 - Viral vectors

Abstract

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 37/08 - Antiallergic agents

Abstract

The invention relates to a microfluidic device (10) comprising: - a support (20) comprising a substrate (25) made of an elastically deformable material; - a study chamber (30, 30a, 30b) extending inside the support (20) having at least one upper wall (32) at least partially formed by the substrate (25), at least one lower wall (34) and at least two side walls (33); - at least one substrate deformation chamber (40, 40a, 40b) at least partially formed by the substrate (25), fluidically independent of the study chamber (30, 30a, 30b) and at least partially extending inside the support (20) along one of the side walls (33) of the study chamber (30), the device being configured so that the deformation of the deformation chamber (40, 40a, 40b) causes the mechanical straining of at least one portion of the upper wall (32) in the study chamber (30).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The invention concerns a method implemented by computer means for visualizing at least a zone of an object in at least one interface, said method comprising the following steps: obtaining at least one image of said zone, said image comprising at least one channel, said image being a 2-dimensional or 3-dimensional image comprising pixels or voxels, a value being associated to each channel of each pixel or voxel of said image, a representation of said image being displayed in the interface, obtaining at least one annotation from a user, said annotation defining a group of selected pixels or voxels of said image, calculating a transfer function based on said selected pixels or voxels and applying said transfer function to the values of each channel of the image, updating said representation of the image in the interface, in which the colour and the transparency of the pixels or voxels of said representation are dependent on the transfer function.

IPC Classes  ?

• G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
• G06T 7/00 - Image analysis
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G06T 7/90 - Determination of colour characteristics
• G06T 11/00 - 2D [Two Dimensional] image generation
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, comprising at least four distinct nucleic acid sequences encoding HPV antigens, to a lentiviral vector particle comprising said vector, to an isolated cell comprising the same, and to a vaccine composition comprising the said lentiviral vector, lentiviral vector particle or cell. The present invention further relates to their implementation in the treatment or prevention of an HPV induced cancer.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The invention relates to the discovery that TMPRSS2 acts as a functional receptor for HKU1. TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and viral pseudotype infection. Catalytically inactive TMPRSS2 mutants do not cleave spike but allow infection, demonstrating that HKU1 binding and processing represent two distinct functions of the receptor. TMPRSS2 binds with high affinity to HKU1 receptor binding domain (RED), but neither to OC43 nor to SARS-CoV-2. Conserved amino acids were identified within the RED that are essential for binding to TMPRSS2 and infection. Anti- TMPRSS2 VHH antibodies were generated that inhibit HKU1 spike binding to TMPRSS2, fusion and infection.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Nanoparticles comprising an antiretroviral drug such as AZT-TP or enfuvirtide encapsulated by a complex of chitosan and optionally a metal cation such as Fe3+, for use in treating or preventing HIV infection via subcutaneous or intramuscular administration. The nanoparticles have a size less than 300 nm and a high drug loading capacity between 20-60% by weight. They are prepared by mixing an aqueous solution of chitosan and metal cation with an aqueous solution of the drug. The chitosan-based nanoparticles provide an effective method to deliver antiretroviral drugs to key HIV reservoir sites with high drug loading and low toxicity.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61P 31/12 - Antivirals

Abstract

The invention relates to an isolated heterodimer of poxvirus A16 and G9 proteins as an immunogen in a subunit or nucleic acid vaccine against poxvirus. The invention provides an engineered heterodimer, nucleic acid encoding the heterodimer, neutralizing antibodies directed against said heterodimer and their use for the prevention, treatment and diagnostics of poxvirus infections and related diseases.

IPC Classes  ?

• A61K 39/285 - Vaccinia virus or variola virus
• C07K 14/07 - Vaccinia virusVariola virus
• A61P 31/20 - Antivirals for DNA viruses

Abstract

A computer-implemented and a device for analysis of a digital cytology slide of a biological sample. The biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, the device including: at least one input configured to receive at least one digital cytology slide obtained from the biological sample; at least one processor configured to: detect cells of interest from the at least one digital cytology image; for each cell of interest, compute a features vector including at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for the subject; at least one output configured to provide the global prediction score.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

This invention thus relates to a computer-implemented and a device for analysis of a digital cytology slide of a biological sample, said biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, said device comprising: at least one input configured to receive at least one digital cytology slide obtained from said biological sample; at least one processor configured to: detect cells of interest from said at least one digital cytology image; for each cell of interest, compute a feature vector comprising at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for said subject; at least one output configured to provide said global prediction score.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06T 7/00 - Image analysis
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

The present invention relates to novel tumor specific peptides derived from the translated ORF sequence from long noncoding RNA (lncRNA), and the uses thereof. The invention more particularly relates to the use of tumor specific peptides in cancer vaccines and cell therapy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to a recombinant protein comprising one or more fragments of pneumococcal surface protein A (PspA) and the adenylate cyclase (CyaA) from Bordetella species, especially Bordetella pertussis, wherein said PspA fragments are selected from clades 1 to 4, or a combination of two or more thereof. Additionally, the invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, especially a DNA sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 12 to 18 and degenerate sequences thereof that encode a recombinant protein as set forth in SEQ ID NOs: 5 to 11 respectively. Further, an immunogenic composition comprising said recombinant protein or said expression cassette, and additionally a pharmaceutically acceptable carrier and/or adjuvant is disclosed. Finally, the invention relates to the use of said recombinant protein, or said expression cassette, or said immunogenic composition for the manufacture of a vaccine for preventing infections caused by Streptococcus pneumoniae, wherein said vaccine offers broad-spectrum protection against different pneumococcal isolates, regardless of serotypes.

IPC Classes  ?

• C07K 14/235 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bordetella (G)
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

System for detecting an antigen comprising: —a first fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a first single domain antibody which is directed against a first epitope of said antigen and —a C-terminal domain which comprises a first fragment of a luciferase having the amino acid sequence SEQ ID NO: 1 or is a variant thereof and —a second fusion protein with no luciferase activity comprising: —a N-terminal domain which comprises a second single domain antibody which is directed against a second epitope of said antigen and —a C-terminal domain which comprises a second fragment of a luciferase having the amino acid sequence SEQ ID NO: 2 or is a variant thereof. Luminescence is emitted in the presence of a substrate when both the first fusion protein and the second fusion protein bind to said antigen.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to combined antibodies against Sarbecoviruses, in particular Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS- CoV-2).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COV-ID-19).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/86 - Viral vectors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to in vitro generation of organized 3D cell structures recapitulating various degrees of early organogenesis, including head-trunk embryo-like structures, using epigenetic remodeling factors. The invention relates in particular to methods of obtaining such organized 3D cell structures from mammalian cells, and to devices, in particular microfluidic platform, to perform such methods. The invention also concerns the use of the thus obtained 3D cell structures in applications of molecule screening, developmental testing, production of physiologically active substances and models for therapeutic investigation or use.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and/or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral

Abstract

The present invention relates to a single domain antibody directed against H2AX with a phosphorylation of serine at position 139 (γ-H2AX), a bivalent molecule comprising said single domain antibody and their use for detecting DNA damage and/or DNA replication stress.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO: 1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

IPC Classes  ?

• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to the potentiation of aminoglycosides through activation of carbohydrate transporters, in particular using nucleosides. The invention encompasses the combination of a nucleoside and an aminoglycoside antibiotic for treating a bacterial infection, wherein the nucleoside enhances the killing of the bacteria by the antibiotic, preferably wherein the nucleoside limits the emergence of antibiotic-resistant bacteria or re-sensitizes antibiotic-resistant bacteria to the killing by the antibiotic.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

IPC Classes  ?

• C12N 15/73 - Expression systems using phage lambda regulatory sequences
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07D 487/04 - Ortho-condensed systems
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The present invention provides cationic peptoid/N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/22 - Polypeptides or derivatives thereof
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The invention relates to a bacterial strain or a combination of bacterial strains, selected from the group consisting of: a Chryseobacterium massiliae strain, a Flavobacterium sp. strain with at least 95% or more Average Nucleotide Identity (ANI) value with the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the Collection Nationale De Culture De Microorganismes (CNCM) on Jan. 24, 2020, and variants thereof, for use as a probiotic in fish(es). The bacterial strain(s) may has(ve) at least 95% or more Average Nucleotide Identity (ANI) value with the Chryseobacterium massiliae strain whose genome comprises SEQ ID NO:2 or as identified by Accession Number No. I-5479 deposited at the CNCM on Jan. 24, 2020, and/or the Flavobacterium sp. strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the CNCM on Jan. 24, 2020, respectively, or variants thereof. Probiotic use may be directed to preventing or minimizing infections by Flavobacterium columnare in fishes. The invention also concerns the said deposited bacterial strains, or probiotic compositions or food products or kits comprising the same, and a method to identify bacterial strain(s) that are probiotic against a pathogen infection.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/20 - Flavobacterium

Abstract

Provided are methods comprising expressing in a recombinant cell a recombinant error-prone reverse transcriptase (RT) and recombinant spacer RNA comprising a target sequence; making a mutagenized cDNA polynucleotide homologous to a DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising a target sequence, and recombinant recombineering system.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12R 1/19 - Escherichia coli

Abstract

The invention relates to compositions and methods for producing and using antibodies against the αlpha7 nicotinic acetylcholine receptor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).

IPC Classes  ?

• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to variants of a DNA polymerase of the polX family capable of synthesizing a nucleic acid molecule without a template strand, or of a functional fragment of such a polymerase, comprising at least one mutation of a residue in at least one specific position, and to uses of said variants, in particular for the synthesis of nucleic acid molecules comprising 3′-OH modified nucleotides.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to a bacterial exopolysaccharide having a repeating structure comprising a series of repeating units represented by formula (I), and to the use of the bacterial exopolysaccharide for immunopotentiation. (In formula (I), n represents an integer of 0 or 1, independently for each repeating unit.)

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 37/04 - Immunostimulants
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12N 1/20 - BacteriaCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

IPC Classes  ?

• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (FcγRs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human FcγRs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human FcγRs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated. These variants did not induce anaphylaxis when injected into mice expressing human FcγRs and could be thus used for the treatment of IgE-mediated disease. Thus invention relates to a recombinant immunoglobulin heavy chain protein which comprises at least one mutation in the Fc portion and recombinant antibody comprising said heavy chain protein.

IPC Classes  ?

• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided are methods comprising expressing in a recombinant cell comprising a Cas gene a recombinant error-prone reverse transcriptase (RT) and a recombinant spacer RNA comprising a target sequence for mutagenesis of a DNA sequence in the Cas gene; making a mutagenized cDNA polynucleotide homologous to the DNA sequence in the recombinant cell; expressing a recombinant recombineering system in the recombinant cell; and recombining the mutagenized cDNA with the homologous DNA sequence of the Cas gene in the recombinant cell. Also provided are recombinant cells comprising recombinant coding sequences for a recombinant Cas protein, recombinant error-prone reverse transcriptase (RT), recombinant spacer RNA comprising the target sequence, and recombinant recombineering system.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/22 - Ribonucleases
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The invention relates to an in vitro method of determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, comprising screening a biological sample of blood or plasma, where the level of at least two biomarkers selected amongst: PGK1, CFP, IGFALS, KRT19, SPRR1A, CPA4, CA2, SERPINA5, MAN2A1, KIF20B, SPEN, JUP, KRT6C, CDSN, KPRP, F13A1, SAA1 (SAA2), LBP, DSP, KRT2, KRT14, ARG1, S100A12, ATAD3B, MAN1A1, HAL, DCD, 07, HP, LEP, IL-8, IL-17, TNF-alpha, USF1, USF2, SELE, MSLN, EGFR, STATS and mtDNA level is determined, with the proviso that the selected biomarkers do not consist of the association of IL-8 and mtDNA level. The method may be for assessing the risk that a human patient has a non-atrophic gastritis (NAG), or an atrophic gastritis/pre-neoplasia (AG/P), or a gastric cancer (GO), or for discriminating between those risks or presence of these conditions. In a particular aspect, the method may comprise as a distinct, simultaneous or parallel step, a step of detecting an Helicobacter pylori infection. The invention also relates to a kit suitable for carrying out such a method, or a set of markers, and the use of the same for determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, or for prognosing or diagnosing a gastric pre-cancer condition or a gastric cancer condition.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 15/86 - Viral vectors
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention proposes a gene therapy approach as a potential curative treatment for the USHER syndrome, in particular for the USH1G syndrome, which is characterized by a profound deafness and a severe vestibular defect in humans. More precisely, the present invention concerns a gene therapy involving administering a vector expressing a SANS protein in a time window that is compatible with human ethics and welfare i.e., in post-natal, infant and adult humans in which the auditory system is completed. The present inventors herein show for the first time that it is possible to restore genetically-impaired auditory and vestibular functions in human beings in subjects suffering from an Usher1G syndrome even when the therapeutic vector is administered at this late stage.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/16 - Otologicals

Abstract

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, or a lentiviral vector particle, in particular a non-integrative lentiviral vector particle, for use for use in the treatment or prevention of an HPV induced cancer, the lentiviral vector comprising at least four distinct nucleic acid sequences; the lentiviral vector particle comprising at least one of the lentiviral vector; the lentiviral vector or the lentiviral vector particle being administered in combination with at least one immune checkpoint inhibitor.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention allows a rapid and early diagnosis of bacterial or viral infection. Such a diagnosis is highly desired among patients admitted in emergency department to allow the initiation of the appropriate treatment. Although no biomarker alone can offer an appropriate diagnosis with sufficient sensitivity and specificity, the present invention defines optimal combinations of biomarkers allowing the diagnosis of infection.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

This disclosure provides proteins, DNA, and dsRNA to improve host-induced gene silencing (HIGS) and spray-induced gene silencing (SIGS) in plant/insect systems, by applying to said plants a composition inducing in same the expression of an Hsc70-4 protein, preferably of a Drosophila melanogaster Hsc70-4 protein.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof, the disaccharide repeating unit of Shigella sonnei being: (I) The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof, the disaccharide repeating unit of Shigella sonnei being: (I)

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 39/112 - SalmonellaShigella
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to a bacteriophage targeting capsular-deficient Klebsiella pneumoniaee (Kp), comprising particular tail fiber polypeptides, which is capable of infecting at least two capsular- deficient Klebsiella pneumoniae of distinct O-types, in particular at least three distinct O-types of capsular-deficient Klebsiella pneumoniae. The invention also relates to a pharmaceutical composition comprising the same, a nucleic acid molecule having at least 99% of identity with the genomic sequence of the said bacteriophage, and the use of the said bacteriophage or composition(s) as a medicament, especially against an infection caused by at least one type of Klebsiella pneumoniae (Kp). The invention also relates to a method for decreasing the bacterial load of at least one Klebsiella pneumoniae (Kp) strain in the environment, making use of said bacteriophage.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates to Lichen planus (LP), and more specifically to no erosive form of LP (NELP). The invention provides an immune signature for LP, which is not found in other cutaneomucosal chronic inflammatory diseases. The invention moreover provides different diagnosis methods and methods of treating NELP, based on this immune signature. The inventors have indeed demonstrated the presence of HPV16-specific activated CTL in blood and lesion samples corresponding to the different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in other cutaneomucosal chronic inflammatory diseases. This HPV16-specific activated CTL is characterized by TCRVβ3+ CD8+ T-cells oligoclonal expansions.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or human cytosolic NADK (HsNADK) enzyme. The present invention relates to benzamide adenine dinucleoside compounds which are useful as inhibitors of NAD kinases, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of bacterial infections.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical

Abstract

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/28 - N-glycosides
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Abstract

The present invention provides an antibody or antigen-binding fragment thereof that specifically binds to a nucleic acid hairpin comprising repeats of CNG nucleotide triplets and their uses.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gas-dermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdennin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AA V2/8 vector expressing at least one USH1 gene product, preferably SANS.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 35/761 - Adenovirus
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to the discovery of the first pathogenic human circovirus in samples from a human hepatitis patient, the capsid of which shows only 39% identity at the amino acid level with the closest known circovirus. This discovery allows for the generation of recombinant nucleic acids, primers, peptides, probes, antibodies, immunogenic compositions, and diagnostic assays specific for human circovirus.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The invention relates to an engineered DNA polymerase D (PolD) and its use for nucleic acid amplification including reverse transcription of RNA.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention concerns Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or Alzheimer's disease-related origin. The present invention also provides compositions, in particular, an oral composition, comprising the Lachnospiraceae spp and Ruminococcus lactaris strains and uses thereof.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE Cε3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.

IPC Classes  ?

• A61K 39/44 - Antibodies bound to carriers
• A61K 39/35 - Allergens
• A61P 37/08 - Antiallergic agents

Abstract

The invention relates to a recombinant lentiviral vector genome comprising a polynucleotide encoding a fusion polypeptide, wherein said fusion protein comprises arranged from N-terminal to C-terminal ends: (i) a first polypeptide comprising a multimerization scaffold which comprises at least one collectin or a fragment thereof suitable to enable self-assembly of multimers of the first polypeptide, fused with at least one antigenic polypeptide; (ii) a second polypeptide comprising a CD40L ectodomain or a receptor binding fragment thereof, in particular the CD40L ectodomain of the human CD40L. The invention also relates to a lentiviral vector and pharmaceutical compositions comprising it.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C12N 15/86 - Viral vectors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)
• A61P 31/06 - Antibacterial agents for tuberculosis

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

It has been discovered that disrupting the stromal capsule restores a better vasculature/tumor perfusion and improve T cells infiltration inside the core of a melanoma. The invention relates to the use of drugs or immunoconjugates that target the transmembrane protease ADAM12 and deplete the cells that express it. Since ADAM12 protein is specifically expressed by stromal cells of the tumor stromal capsule and around vessels in models for prostate cancer, neuroendocrine pancreatic cancer and melanoma, an ADAM12 inhibitor is useful in anti-tumor therapies as an adj uvant. The invention encompasses methods, compositions, and kits containing ADAM12 inhibitors for use in the depletion of ADAM12+ stromal cells in cancer patient, particularly together with ant-tumor compounds and treatments.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides anti-S-HBs antibodies and methods of using the same.

IPC Classes  ?

• A61P 31/20 - Antivirals for DNA viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention is in the field of therapeutic drugs to treat malaria. In particular, the invention provides oxo-azaheterocyclic derivatives for use in the treatment of malaria, for example drug-resistant malaria.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 33/06 - Antimalarials
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 49/00 - Preparations for testing in vivo
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

IPC Classes  ?

• A01N 1/00 - Preservation of bodies of humans or animals, or parts thereof
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01P 7/04 - Insecticides

Abstract

The present invention relates to a composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

IPC Classes  ?

• A01N 1/00 - Preservation of bodies of humans or animals, or parts thereof
• A01N 25/04 - Dispersions or gels
• A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01P 7/04 - Insecticides
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants

Abstract

The invention concerns a multivalent immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV), wherein each valence is constituted by a recombinant live attenuated Mopeia virus in which the MOPV nucleoprotein (NP) has attenuated exonuclease activity and the encoded glycoprotein precursor (GPC) is from a New World arenavirus selected from one of the following arenaviruses: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV). The invention also concerns a combination of active ingredients, a composition or vaccine, or a therapeutically effective composition, comprising such recombinant live attenuated Mopeia viruses (MOPV) for use in eliciting a protective immune response in a mammalian host against a New World arenavirus infection. The invention also concerns a method of preparing such recombinant live attenuated Mopeia viruses (MOPV) in a eukaryotic host cell and a method of preparing a multivalent, in particular a pentavalent, immunogenic composition comprising recombinant live attenuated Mopeia viruses (MOPV) expressing a GPC protein of a New World arenavirus selected among: Machupo virus (MACV), Sabia virus (SABV), Chapare virus (CHAPV), Junin virus (JUNV) and Guanarito virus (GTOV).

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/02 - Recovery or purification
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/86 - Viral vectors

Abstract

su-cosu-co-2su-co-2, representing first-in-class molecules to inhibit MFSD2A LPCs uptake and increase transcytosis rate.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to novel means and processes for the detection of a virus in a biological sample comprising cells infected by the virus. In particular, the invention relates to a fluorescent reporter protein designed as a recombinant inactive form of flipGFP suitable for specific activation by viral components in particular by viral proteins, such as viral protease, wherein the viral component recognizes a cleavage site inserted in the recombinant flipGFP. The fluorescent reporter protein is suitable for use in an in vitro method of detection of virus infection in a biological sample when the virus is related to the viral components activating the inactive form of flipGFP into an active fluorescent flipGFP in a biological sample, especially a sample comprising cells, in particular unaltered cells.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

A method of inducing a protective immune response against Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2), comprising administering to the upper respiratory tract of a subject an effective amount of an agent that induces a protective immune response against SARS-CoV-2. A dosage form for administration to the upper respiratory tract of a pseudotyped lentiviral vector particle encoding a Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2) spike (S) protein or a derivative or fragment thereof.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to reagents and methods for the rapid detection of the presence and/or absence of SARS-CoV-2 or other betacoronavirus group B/C nucleic acid in a sample and their use for the diagnosis of an infection or the detection of an environmental contamination by SARS-CoV-2 or other betacoronavirus group B/C.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 25/24 - Antidepressants
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The invention relates to a method for reprogramming CD8+ T cells to enhance their therapeutic potential and its applications, in particular in adoptive T cell therapy for the treatment of infectious diseases and cancer.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents

Abstract

Method for detecting spatial coupling comprising the steps of: a. providing a set of data, b. identifying and segmenting a first and a second sets of objects of interest, wherein the objects of the second set are assimilated to punctual objects, c. determining, using a level set function, an expected number of objects of the second set present within a specified range of distances to at least one given object of the first set in case there were no interactions between said at least one given object of the first set and the objects of the second set, d. determining, using a level set function, an actual number of objects of the second set within the same range of distances to the at least one given object of the first set, and e. comparing said expected amount and said determined amount.

IPC Classes  ?

• G06T 7/11 - Region-based segmentation
• G06T 7/00 - Image analysis
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods

Abstract

The application generally relates to enhanced recombinant nucleic acid constructs comprising a cDNA molecule encoding a full length antigenomic (+) RNA strand of a non-segmented negative-sense single-stranded RNA virus for expressing at least one heterologous polypeptide, protein, antigen, or antigenic fragment thereof. The application more particularly relates to constructs with multiple ATUs localized within a single intergenic region of a virus. The application also relates to the association between a construct with multiple ATUs and BAG plasmid to facilitate the introduction and expression of large inserts.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 39/12 - Viral antigens

Abstract

A method for generating a color-faithful extended-depth-of-field (EDF) image from a color volume of 2D images acquired at different focal depths using a microscope. The method involves: generating a grayscale volume; applying invertible color-to-grayscale transformation to the volume; applying wavelet transform to the grayscale volume to obtain a 3D wavelet-coefficient-matrix (WCM); selecting wavelet coefficients using a coefficient selection rule; generating a 2D-WCM and a 2D coefficient-map (CM); applying inverse transformation of the wavelet transform to the 2D-WCM to obtain a 2D grayscale EDF image; generating a 2D color-composite(CC) image; applying inverse transformation of the color-to-grayscale transformation to the 2D grayscale EDF image to obtain a 2D color EDF image; converting the 2D-CC image and the 2D color EDF image into a color space including chromaticity and intensity component(s); and concatenating, chromaticity component(s) of the 2D-CC image and intensity component(s) of the 2D color EDF image, to obtain a color-faithful EDF image.

IPC Classes  ?

• G06F 17/00 - Digital computing or data processing equipment or methods, specially adapted for specific functions
• G06T 5/20 - Image enhancement or restoration using local operators
• G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
• G06T 7/00 - Image analysis
• G06V 10/56 - Extraction of image or video features relating to colour
• H04N 1/40 - Picture signal circuits
• H04N 23/67 - Focus control based on electronic image sensor signals